FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W200877045> ?p ?o ?g. }

• W200877045 endingPage "76" @default.
• W200877045 startingPage "2665" @default.
• W200877045 abstract "Immunotherapy has always represented a very attractive fourth-modality therapeutic approach, especially in light of the many shortcomings of conventional surgery, radiation, and chemotherapies in the management of cancer. Subsets of neoplastically transformed cells have been shown to (re-)express on their surface molecules which are not typically present on the surface of neighboring normal cells. In some instances, especially in malignant melanomas, cytotoxic T lymphocytes (CTLs) directed against such tumor associated antigens (TAAs) have been isolated. The cancer vaccine approach to therapy is based on the notion that the immune system could possibly mount a rejection strength response against the neoplastically transformed cell conglomerate. However, due to the low immunogenicity of TAAs, downregulation of MHC molecules, the lack of adequate costimulatory molecule expression, secretion of immunoinhibitory cytokines, etc., such expectations are rarely fulfilled. Various approaches have been explored ranging from the use of irradiation inactivated whole-cell vaccines derived from both autologous and allogeneic tumors (even tumor cell lines), and genetically modified versions of such cellular vaccines which aim at correcting costimulatory dysfunction or altering the in situ humoral milieu to aid immune recognition and activation. Anti-idiotype vaccines, based on cancer cell associated idiotypes, have also been explored which aim at increasing immunogenicity through in vivo generation of vigorous immune responses. Dendritic cell (DC) vaccines seek to improve the presentation of TAAs to naive T lymphocytes. Unfortunately, there is always the possibility of faulty antigen presentation which could result in tolerance induction to the antigens contained within the vaccine, and subsequent rapid tumor progression. The theoretical basis for all of these approaches is very well founded. Animal models, albeit highly artificial, have yielded promising results. Clinical trials in humans, however, have been somewhat disappointing. Although general immune activation directed against the target antigens contained within the cancer vaccine has been documented in most cases, reduction in tumor load has not been frequently observed, and tumor progression and metastasis usually ensue, possibly following a slightly extended period of remission. The failure of cancer vaccines to fulfill their promise is due to the very relationship between host and tumor: through a natural selection process the host leads to the selective enrichment of clones of highly aggressive neoplastically transformed cells, which apparently are so dedifferentiated that they no longer express cancer cell specific molecules. Specific activation of the immune system in such cases only leads to lysis of the remaining cells expressing the particular TAAs in the context of the particular human leukocyte antigen (HLA) subclass and the necessary costimulatory molecules. The most dangerous clones of tumor cells however lack these features and thus the cancer vaccine is of little use. The use of cancer vaccines seems, at present, destined to remain limited to their employment as adjuvants to both traditional therapies and in the management of minimal residual disease following surgical resection of the primary cancer mass." @default.
• W200877045 created "2016-06-24" @default.
• W200877045 creator A5028334828 @default.
• W200877045 creator A5052277840 @default.
• W200877045 creator A5056838718 @default.
• W200877045 date "2000-08-23" @default.
• W200877045 modified "2023-10-17" @default.
• W200877045 title "Failure of cancer vaccines: the significant limitations of this approach to immunotherapy." @default.
• W200877045 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10953341" @default.
• W200877045 hasPublicationYear "2000" @default.
• W200877045 type Work @default.
• W200877045 sameAs 200877045 @default.
• W200877045 citedByCount "57" @default.
• W200877045 countsByYear W2008770452013 @default.
• W200877045 countsByYear W2008770452014 @default.
• W200877045 countsByYear W2008770452015 @default.
• W200877045 countsByYear W2008770452016 @default.
• W200877045 countsByYear W2008770452017 @default.
• W200877045 countsByYear W2008770452018 @default.
• W200877045 countsByYear W2008770452019 @default.
• W200877045 countsByYear W2008770452020 @default.
• W200877045 countsByYear W2008770452022 @default.
• W200877045 countsByYear W2008770452023 @default.
• W200877045 crossrefType "journal-article" @default.
• W200877045 hasAuthorship W200877045A5028334828 @default.
• W200877045 hasAuthorship W200877045A5052277840 @default.
• W200877045 hasAuthorship W200877045A5056838718 @default.
• W200877045 hasConcept C121608353 @default.
• W200877045 hasConcept C147483822 @default.
• W200877045 hasConcept C147969180 @default.
• W200877045 hasConcept C154317977 @default.
• W200877045 hasConcept C167672396 @default.
• W200877045 hasConcept C202751555 @default.
• W200877045 hasConcept C203014093 @default.
• W200877045 hasConcept C207936829 @default.
• W200877045 hasConcept C2776090121 @default.
• W200877045 hasConcept C2777701055 @default.
• W200877045 hasConcept C2778170410 @default.
• W200877045 hasConcept C2778378633 @default.
• W200877045 hasConcept C2780674031 @default.
• W200877045 hasConcept C2780868878 @default.
• W200877045 hasConcept C502942594 @default.
• W200877045 hasConcept C54355233 @default.
• W200877045 hasConcept C55493867 @default.
• W200877045 hasConcept C83464605 @default.
• W200877045 hasConcept C86803240 @default.
• W200877045 hasConcept C8891405 @default.
• W200877045 hasConceptScore W200877045C121608353 @default.
• W200877045 hasConceptScore W200877045C147483822 @default.
• W200877045 hasConceptScore W200877045C147969180 @default.
• W200877045 hasConceptScore W200877045C154317977 @default.
• W200877045 hasConceptScore W200877045C167672396 @default.
• W200877045 hasConceptScore W200877045C202751555 @default.
• W200877045 hasConceptScore W200877045C203014093 @default.
• W200877045 hasConceptScore W200877045C207936829 @default.
• W200877045 hasConceptScore W200877045C2776090121 @default.
• W200877045 hasConceptScore W200877045C2777701055 @default.
• W200877045 hasConceptScore W200877045C2778170410 @default.
• W200877045 hasConceptScore W200877045C2778378633 @default.
• W200877045 hasConceptScore W200877045C2780674031 @default.
• W200877045 hasConceptScore W200877045C2780868878 @default.
• W200877045 hasConceptScore W200877045C502942594 @default.
• W200877045 hasConceptScore W200877045C54355233 @default.
• W200877045 hasConceptScore W200877045C55493867 @default.
• W200877045 hasConceptScore W200877045C83464605 @default.
• W200877045 hasConceptScore W200877045C86803240 @default.
• W200877045 hasConceptScore W200877045C8891405 @default.
• W200877045 hasIssue "4" @default.
• W200877045 hasLocation W2008770451 @default.
• W200877045 hasOpenAccess W200877045 @default.
• W200877045 hasPrimaryLocation W2008770451 @default.
• W200877045 hasRelatedWork W200877045 @default.
• W200877045 hasRelatedWork W203177496 @default.
• W200877045 hasRelatedWork W2172043331 @default.
• W200877045 hasRelatedWork W2261783325 @default.
• W200877045 hasRelatedWork W2285466634 @default.
• W200877045 hasRelatedWork W2325003093 @default.
• W200877045 hasRelatedWork W2400007530 @default.
• W200877045 hasRelatedWork W2413922971 @default.
• W200877045 hasRelatedWork W4210722327 @default.
• W200877045 hasRelatedWork W4213225989 @default.
• W200877045 hasVolume "20" @default.
• W200877045 isParatext "false" @default.
• W200877045 isRetracted "false" @default.
• W200877045 magId "200877045" @default.
• W200877045 workType "article" @default.